drugset
drugset / Trial / NCT06408870

A Study in Healthy People to Compare How 2 Different Low Dose Formulations of BI 1015550 Are Taken up in the Body

NCT06408870 ↗

Phase 1 Completed 64 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The main objective of this trial is to establish the bioequivalence of the BI 1015550 Formulation C2 (Test, T) and the BI 1015550 Formulation C1 (Reference, R) following a single oral dose administration.

Timeline

Start
2024-06-06
Primary completion
2024-08-28
Completion
2024-08-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Nerandomilast Small molecule — Oral

Indications

No indication recorded.